AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

(RTTNews) - AstraZeneca (AZN.L, AZN) said Imfinzi or durvalumab in combination with chemotherapy has been recommended for approval in the European Union for the treatment of adults with resectable ...

AstraZeneca Pharma India Ltd has received the nod from the Central Drugs Standard Control Organisation (CDSCO) to import and ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...